Neuroendokrine Tumoren des Gastrointestinaltraktes

Die neuroendokrinen Tumoren des Gastrointestinaltraktes einschließlich des Pankreas umfassen ein weites Spektrum potenziell maligner Neoplasien, die immer häufiger diagnostiziert werden. Dieser Beitrag gibt eine Übersicht über diese Tumoren – und beschreibt insbesondere die Möglichkeiten der endoskopischen Therapie sowie die Standards und Neuentwicklungen der Systemtherapien.

Schlüsselwörter

neuroendokriner Tumor - Proliferationsrate Ki67 - Somatostatinanaloga (SSA) - Tyrosinkinaseinhibitor (TKI) - Peptid-Radio-Rezeptor-Therapie (PRRT)

• Literatur

• 1 Xu Z, Wang L, Dai S. et al. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open 2021; 4: e2124750
• 2 Rindi G, Mete O, Uccella S. et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 2022; 33: 115-154
• 3 Hofland J, Falconi M, Christ E. et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 2023; 35: e13318
• 4 Rinke A, Wiedenmann B, Auernhammer C. et al. S2k-Leitlinie Neuroendokrine Tumore. Z Gastroenterol 2018; 56: 583-681
• 5 Panzuto F, Ramage J, Pritchard DM. et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3. J Neuroendocrinol 2023; 35: e13306
• 6 Rinke A, Ambrosini V, Dromain C. et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol 2023; 35: e13309
• 7 Sadowski SM, Neychev V, Millo C. et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34: 588-596
• 8 Wannhoff A, Nabi Z, Moons LMG. et al. International, multicenter analysis of endoscopic full-thickness resection of duodenal neuroendocrine tumors. Am J Gastroenterol 2025;
• 9 Rinke A, Müller H-H, Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663
• 10 Caplin ME, Pavel M, Ćwikła JB. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 224-233
• 11 Chan JA, Geyer S, Zemla T. et al. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med 2025; 392: 653-665
• 12 Kunz PL, Graham NT, Catalano PJ. et al. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol 2023; 41: 1359-1369
• 13 Yao JC, Shah MH, Ito T. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523
• 14 Raymond E, Dahan L, Raoul J-L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513
• 15 Singh S, Halperin D, Myrehaug S. et al. [¹⁷⁷Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 2024; 403: 2807-2817
• 16 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376: 125-135
• 17 Pavlakis N, Ransom DT, Wyld D. et al. Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies ofLu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +/− Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours(NETs). J Clin Oncol 2022; 40 (Suppl. 16) abstr 4122
• 18 Baum RP, Zhang J, Schuchardt C. et al. First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med 2021; 62: 1571-1581
• 19 Dasari A, Shen C, Halperin D. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3: 1335-1342